Mylan - Now a Part of Viatris
Mylan is now part of Viatris, a new global healthcare company committed to empowering people to live healthier at every stage of life. We encourage you to learn more about our commitment to increasing access to quality medicines for patients when and where they need them.
Mylan Receives FDA Approval for Levothyroxine Sodium Tablets PITTSBURGH, June 24 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application
Mylan's Board of Directors, Mylan will acquire 100% of the shares of the various businesses comprising Merck Generics for a cash consideration of EUR 4.9 billion ($6.7 billion).
Mylan Reports Fourth Quarter & Fiscal 2007 Adjusted Diluted EPS …
PITTSBURGH, Pa., May 24, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced its financial results for the fourth quarter and fiscal year ended March 31, 2007.
This Amendment No.1 relates to the Registration Statement on Form S-8 filed by Mylan Laboratories Inc. (the “Registrant”) with the Securities and Exchange Commission (the “Commission”) on July 25, 2000 (File No. 333-42182) (the “Registration Statement”) relating to the Mylan Profit Sharing 401(k) Plan (the “401(k) Plan”).
Mylan Laboratories Inc. Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.
Mylan's Vice Chairman and Chief Executive Officer Robert J. Coury, stated, "These filings bring us one step closer to the consummation of the pending acquisition and realizing the potential shareholder value that will be created from the combination of Mylan Laboratories and King Pharmaceuticals."
PITTSBURGH, June 15 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) announced today that it will change the name of its branded subsidiary, currently known as Bertek Pharmaceuticals Inc., to Mylan Bertek Pharmaceuticals Inc.
Gary Sphar was appointed to the new position of Executive Vice President and Chief Financial Officer of Mylan Pharmaceuticals. Mr. Sphar has been employed in various accounting and finance positions by Mylan since 1992, including most recently as Vice President and Corporate Controller of Mylan Laboratories and Vice President-Finance of Mylan
PITTSBURGH, April 7 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that President and Chief Operating Officer Louis J. DeBone will retire later this year after a distinguished 30-year career with the Company.
- 某些结果已被删除